Kopran has received approval from UKMHRA for finished dosage forms facility located at Khopoli in Maharashtra.
"The approval for this facility shall enable the company to supply finished dosage forms to the UK and the European market for which necessary marketing tie-ups are being entered into," the company said in a BSE filing.
Following the announcement, shares of the company jumped 19.81 per cent to settle at Rs 25.40 on the BSE today.
The UK authority has granted the certificate of compliance with principles and guidelines of good manufacturing practice for the Khopoli plant.
The facility also has approvals from regulatory authorities of countries including the Medicines Control Council, South Africa (MCC) and the Therapeutic Goods Administration, Australia (TGA).